Solid Therapeutics ApS
Key figures
- Return on assets
- -59.2%
- Return on equity
- –
- Current ratio
- 1,162.4%
- Equity ratio
- -224.4%
Profit and loss
| Reporting period | |
|---|---|
Gross profit | -1,687,751 |
Operating profit | -4,051,662 |
Finance income | 31,079 |
Finance expenses | 1,314,782 |
Tax expense | -979,740 |
Profit/loss for the year | -4,355,625 |
Employees
| Reporting period | |
|---|---|
Avg. employees | 3 |
Personnel costs | 2,363,911 DKK |
Balance sheet
| Reporting period | |
|---|---|
Cash and cash equivalents | 5,817,513 |
Current assets | 6,842,364 |
Total assets | 6,842,364 |
Equity | -15,353,766 |
Liabilities | 22,196,130 |
Current liabilities | 588,641 |
Working capital
| Reporting period | |
|---|---|
Other current receivables | 45,111 |
Trade payables | 314,917 |
Capital and dividend
| Reporting period | |
|---|---|
Contributed capital | 40,000 |
Retained earnings | -15,393,766 |
Annual report highlights
Business and development
The company's object is to engage in activities within pharmaceutical drug discovery and development.
Financial review
The company's income statement for the year ended 31 December 2025 shows a loss of DKK 4.355.625, and the balance sheet at 31 December 2025 shows negative equity of DKK 15.353.766.
Expected development of the company, including specific prerequisites and uncertaintiesThe Company has lost its entire share capital. Despite this capital loss, Management assesses that the Company continues to have a sufficient capital base and liquidity to support ongoing operations. Management continuously monitors the capital structure and the potential need to re-establish equity. Together with the Board of Directors, Management is actively working to secure additional funding during the financial year 2026. Furthermore, Management assesses that the Company will obtain the necessary funding to continue its planned operations.
With the grants and loans already secured during 2025, the Company has the financial resources and liquidity to carry out its planned activities for the next 12 months.
Risks and material matters
The Company has lost its entire share capital. Despite this capital loss, Management assesses that the Company continues to have a sufficient capital base and liquidity to support ongoing operations. Management continuously monitors the capital structure and the potential need to re-establish equity. Together with the Board of Directors, Management is actively working to secure additional funding during the financial year 2026. Furthermore, Management assesses that the Company will obtain the necessary funding to continue its planned operations.
With the grants and loans already secured during 2025, the Company has the financial resources and liquidity to carry out its planned activities for the next 12 months.
No events have occurred after the balance sheet date which could significantly affect the company's financial position.
Commitments and security
The company has no contingent liabilities.
The company has not provided any security or other collateral at 31 December 2025.
Create a free account to see up to 9 years of financial history
Create free account